These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33466496)

  • 1. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Nakano M; Suga H; Yamaguchi T; Kawaguchi T; Kuromatsu R; Noguchi K; Koga H; Torimura T
    Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33466496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
    Shimose S; Iwamoto H; Niizeki T; Tanaka M; Shirono T; Moriyama E; Noda Y; Nakano M; Suga H; Kuromatsu R; Torimura T; Koga H; Kawaguchi T
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis.
    Shimose S; Kawaguchi T; Tanaka M; Iwamoto H; Miyazaki K; Moriyama E; Suzuki H; Niizeki T; Shirono T; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Oncol Lett; 2020 Sep; 20(3):2257-2265. PubMed ID: 32782543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
    Kuroda H; Oikawa T; Ninomiya M; Fujita M; Abe K; Okumoto K; Katsumi T; Sato W; Igarashi G; Iino C; Endo T; Tanabe N; Numao H; Fukuda S; Iijima K; Masamune A; Ohira H; Ueno Y; Takikawa Y
    Liver Cancer; 2022 Jul; 11(4):383-396. PubMed ID: 35978602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Mawatari S; Tamai T; Kumagai K; Saisyoji A; Muromachi K; Toyodome A; Taniyama O; Sakae H; Ijuin S; Tabu K; Oda K; Hiramine Y; Moriuchi A; Sakurai K; Kanmura S; Ido A
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.
    Shimose S; Tanaka M; Iwamoto H; Niizeki T; Shirono T; Aino H; Noda Y; Kamachi N; Okamura S; Nakano M; Kuromatsu R; Kawaguchi T; Kawaguchi A; Koga H; Yokokura Y; Torimura T
    Hepatol Res; 2019 Aug; 49(8):919-928. PubMed ID: 30969006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
    Lee J; Han JW; Sung PS; Lee SK; Yang H; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Oh JS; Chun HJ; Bae SH; Choi JY; Yoon SK
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma.
    Long F; Chen S; Li R; Lin Y; Han J; Guo J; Chen Y; Li C; Song P
    Med Oncol; 2023 Apr; 40(5):147. PubMed ID: 37043113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy.
    Cai XR; Chen ZH; Liu MM; Lin JX; Zhang XP; Chen J; Lin Q; Ma XK; Wen JY; Xie SD; Wu XY; Dong M
    J Cancer; 2018; 9(13):2380-2388. PubMed ID: 30026834
    [No Abstract]   [Full Text] [Related]  

  • 11. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma.
    Ma XL; Zhou JY; Gao XH; Tian L; Wu J; Zhang CY; Zhou Y; Dai Q; Wang BL; Pan BS; Yang XR; Guo W
    Clin Chim Acta; 2016 Nov; 462():15-22. PubMed ID: 27520748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
    Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
    Tsuchiya K; Kurosaki M; Sakamoto A; Marusawa H; Kojima Y; Hasebe C; Arai H; Joko K; Kondo M; Tsuji K; Sohda T; Kimura H; Ogawa C; Uchida Y; Wada S; Kobashi H; Furuta K; Shigeno M; Kusakabe A; Akahane T; Narita R; Yoshida H; Mitsuda A; Ide Y; Matsushita T; Izumi N; On Behalf Of Japanese Red Cross Liver Study Group
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
    Shimose S; Iwamoto H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Nakano M; Suga H; Kuromatsu R; Yamaguchi T; Kawaguchi T; Tanaka M; Noguchi K; Koga H; Torimura T
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
    Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
    Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
    Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
    Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.